NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.08
Percentage change -0.75	%

Peers: LLY MRK PFE JNJ BMY AMGN GILD REGN VRTX BMRN

| Held by: VTI IWM XBI VXF IWO VTWO IBB SCHA VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-3.87	Insider Own	4.16%	Shs Outstand	86.05M	Perf Week	-2.50%
Market Cap	906.94M	Forward P/E	-	EPS next Y	-2.70	Insider Trans	-0.08%	Shs Float	82.47M	Perf Month	-25.51%
Income	-331.20M	PEG	-	EPS next Q	-1.00	Inst Own	115.48%	Short Float	26.35%	Perf Quarter	-32.61%
Sales	43.72M	P/S	20.74	EPS this Y	-1.37%	Inst Trans	3.50%	Short Ratio	9.47	Perf Half Y	-37.00%
Book/sh	2.50	P/B	4.22	EPS next Y	28.49%	ROA	-55.96%	Short Interest	21.73M	Perf Year	-47.51%
Cash/sh	5.95	P/C	1.77	EPS next 5Y	27.48%	ROE	-93.70%	52W Range	8.58 - 25.07	Perf YTD	-20.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.16%	ROI	-60.64%	52W High	-57.96%	Beta	0.74
Dividend TTM	-	Quick Ratio	5.75	Sales past 5Y	73.25%	Gross Margin	-0.37%	52W Low	22.84%	ATR (14)	0.84
Dividend Ex-Date	-	Current Ratio	5.80	EPS Y/Y TTM	-19.97%	Oper. Margin	-786.03%	RSI (14)	46.95	Volatility	2.35% 7.79%
Employees	270	Debt/Eq	1.61	Sales Y/Y TTM	-	Profit Margin	-757.52%	Recom	1.23	Target Price	35.58
Option/Short	Yes / Yes	LT Debt/Eq	1.54	EPS Q/Q	-15.89%	Payout	-	Rel Volume	0.79	Prev Close	10.62
Sales Surprise	21.71%	EPS Surprise	21.75%	Sales Q/Q	-	Earnings	May 05 AMC	Avg Volume	2.29M	Price	10.54
SMA20	0.15%	SMA50	-10.04%	SMA200	-31.53%	Trades		Volume	1,808,473	Change	-0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	UBS	Buy	$37
Jun-28-24	Initiated	Jefferies	Buy	$37
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$36 → $23
Dec-22-23	Initiated	Mizuho	Buy	$45
Oct-25-23	Initiated	BofA Securities	Buy	$29
Oct-11-23	Initiated	Goldman	Buy	$30
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy	$40
Apr-17-23	Resumed	BTIG Research	Buy	$34
Jan-31-23	Initiated	Stifel	Buy	$37
Jan-03-23	Initiated	JP Morgan	Overweight	$41
Jul-28-22	Resumed	B. Riley Securities	Buy	$31
Apr-11-22	Initiated	H.C. Wainwright	Buy	$31
Feb-15-22	Initiated	Goldman	Buy	$37
Jun-04-21	Resumed	Robert W. Baird	Outperform	$30 → $31
May-25-21	Initiated	Citigroup	Buy	$24
Feb-18-21	Initiated	B. Riley Securities	Buy	$30
Dec-03-20	Initiated	Stifel	Buy	$32
May-22-20	Upgrade	Citigroup	Neutral → Buy	$26 → $23
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral	$25 → $15

Show Previous Ratings

May-29-25 07:00AM	Syndax Announces Participation in June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr) (GlobeNewswire) -8.93%
May-12-25 04:01PM	Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer (GlobeNewswire) -7.28%
May-09-25 09:55AM	Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? (Zacks)
May-08-25 07:00AM	Syndax Announces Participation in May Investor Conferences (GlobeNewswire) +10.21%
04:01PM	Loading…
May-07-25 04:01PM	Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood (GlobeNewswire) -6.11%
May-06-25 01:13PM	Q1 2025 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -21.59%
03:06AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Syndax: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-02-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
09:26AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-28-25 07:00AM	Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
04:05PM	Loading…
Apr-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -9.71%
Apr-02-25 07:00AM	Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) +7.99%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha) +7.47%
Mar-05-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... (GuruFocus.com)
Mar-03-25 08:15AM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:13AM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-25 07:07AM	Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 07:00AM	Syndax Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-24-25 07:00AM	Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025 (GlobeNewswire)
Feb-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-25 07:00AM	Syndax Announces Participation in February Investor Conferences (PR Newswire)
Jan-15-25 05:34PM	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes (PR Newswire)
07:00AM	Loading…
Jan-13-25 07:00AM	Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-07-25 07:00AM	Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-03-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-09-24 07:30AM	Syndax Announces Additional Positive Data for Revuforj (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial (PR Newswire) -8.52%
Dec-07-24 06:15PM	Syndax Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting (PR Newswire)
Dec-04-24 01:32PM	Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-27-24 07:00AM	Syndax Announces Participation at the Citi 2024 Global Healthcare Conference (PR Newswire)
Nov-18-24 07:12AM	Syndax secures FDA OK for new kind of leukemia drug (BioPharma Dive)
06:39AM	FDA approves Syndaxs Revuforj to treat leukaemia (Pharmaceutical Technology)
Nov-15-24 05:29PM	Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation (PR Newswire) -5.72%
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-13-24 01:06PM	Syndaxs stock sinks by 25% despite AML trial meeting primary endpoint (Pharmaceutical Technology)
07:21AM	Syndaxs revumenib meets primary results in AML trial (TipRanks)
Nov-12-24 01:07PM	Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer (Benzinga) -25.57%
07:00AM	Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib (PR Newswire)
Nov-07-24 12:32AM	Q3 2024 Royalty Pharma PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 12:16PM	Q3 2024 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +8.43%
05:00AM	Moderna said to shuffle sales leadership; Vertex records first Casgevy sale (BioPharma Dive)
02:23AM	Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-05-24 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Syndax: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
09:01AM	Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 (PR Newswire)
09:00AM	Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting (PR Newswire)
09:00AM	Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting (PR Newswire)
04:32AM	Syndax agrees funding with Royalty Pharma for Niktimvo US sales (Pharmaceutical Technology)
Nov-04-24 04:15PM	Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo (GlobeNewswire)
04:01PM	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo (PR Newswire)
Nov-01-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Syndax Announces Participation in November Investor Conferences (PR Newswire)
Oct-29-24 07:00AM	Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 (PR Newswire)
Oct-18-24 03:03PM	State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals (GuruFocus.com)
Oct-09-24 03:54PM	Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Oct-04-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-18-24 05:15PM	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease (PR Newswire)
Sep-06-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 12:01AM	Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-15-24 12:32PM	FDA greenlights Incyte and Syndaxs GvHD drug Niktimvo (Pharmaceutical Technology)
10:11AM	FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication (Benzinga)
Aug-14-24 05:34PM	Incyte and Syndax Announce U.S. FDA Approval of Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) (Business Wire)
Aug-12-24 07:00AM	Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia (PR Newswire)
Aug-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -6.56%
Aug-01-24 04:46PM	Syndax: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update (PR Newswire)
08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jul-30-24 03:07PM	3 Biotech Stocks That Could Make Your Summer Unforgettable (InvestorPlace)
Jul-29-24 02:42PM	FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks (Investopedia) -10.21%
07:01AM	Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia (PR Newswire)
Jul-25-24 09:55AM	Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet (Zacks)
07:00AM	Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 (PR Newswire)
Jul-09-24 09:55AM	Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade (Zacks) +6.81%
Jul-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire)
Jun-14-24 07:00AM	Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress (PR Newswire)
Jun-10-24 07:30AM	Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger (GlobeNewswire)
Jun-06-24 07:00AM	Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC (PR Newswire)
Jun-05-24 07:00AM	Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
Jun-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-15-24 04:05PM	Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors (PR Newswire)
May-12-24 08:26AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:00AM	Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference (PR Newswire)
03:03AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:22AM	Syndax Pharmaceuticals Q1 Net Loss Widens (MT Newswires)
07:27AM	Syndax: Q1 Earnings Snapshot (Associated Press Finance)
07:06AM	Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update (PR Newswire)
May-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-01-24 07:00AM	Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 (PR Newswire)
Apr-10-24 04:05PM	Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum (PR Newswire)

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Botwood Nicholas A.J.	Head of R&D, CMO	May 16 '25	Buy	8.99	11,765	105,826	35,165	May 19 04:03 PM
Huber Martin H. Jr.	Director	May 19 '25	Buy	8.99	5,000	44,950	79,000	May 19 04:02 PM
Katkin Keith	Director	May 19 '25	Buy	9.11	10,000	91,120	100,000	May 19 04:01 PM
Metzger Michael A	Chief Executive Officer	Mar 14 '25	Option Exercise	7.20	6,074	43,733	306,195	Mar 17 06:01 AM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Option Exercise	7.20	7,814	56,261	307,935	Mar 06 04:10 PM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Sale	15.05	7,814	117,564	300,121	Mar 06 04:10 PM
MICHAEL METZGER	Officer	Mar 04 '25	Proposed Sale	15.48	13,888	214,986		Mar 04 05:10 PM
Goldan Keith A.	Chief Financial Officer	Feb 10 '25	Sale	15.50	3,777	58,559	90,746	Feb 12 05:16 PM
Metzger Michael A	Chief Executive Officer	Feb 10 '25	Sale	15.50	13,288	206,017	300,121	Feb 12 05:15 PM
Gallagher Neil	President, Head of R&D	Feb 10 '25	Sale	15.50	4,618	71,597	85,095	Feb 12 05:13 PM
Goldan Keith A.	Officer	Feb 10 '25	Proposed Sale	15.50	3,777	58,559		Feb 10 03:29 PM
Metzger Michael A	Officer	Feb 10 '25	Proposed Sale	15.50	13,288	206,017		Feb 10 03:20 PM
Gallagher Neil	Officer	Feb 10 '25	Proposed Sale	15.50	4,618	71,597		Feb 10 03:17 PM
Goldan Keith A.	Chief Financial Officer	Jun 14 '24	Buy	20.03	1,250	25,037	52,623	Jun 17 09:26 AM

Open in Screener

MRSN

Mersana Therapeutics Inc

May 30 • 04:00PM ET

0.3437

Dollar change -0.0053
Percentage change -1.52	%

Healthcare • Biotechnology • USA • NASD

MRSN Mersana Therapeutics Inc daily Stock Chart

Peers: AMGN ALNY EXEL SRPT NBIX SAVA BPMC AGIO IMMP

| Held by: VTI IWM VXF VTWO IWO IWN IBB IWC CHNA QQQS

Index	RUT	P/E	-	EPS (ttm)	-0.60	Insider Own	22.30%	Shs Outstand	124.63M	Perf Week	-11.87%
Market Cap	42.84M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	-0.30%	Shs Float	96.84M	Perf Month	-20.61%
Income	-74.01M	PEG	-	EPS next Q	-0.15	Inst Own	50.21%	Short Float	13.20%	Perf Quarter	-34.33%
Sales	34.01M	P/S	1.26	EPS this Y	-4.59%	Inst Trans	-21.60%	Short Ratio	4.34	Perf Half Y	-82.82%
Book/sh	-0.25	P/B	-	EPS next Y	1.71%	ROA	-47.62%	Short Interest	12.78M	Perf Year	-85.68%
Cash/sh	0.82	P/C	0.42	EPS next 5Y	-8.64%	ROE	-505.14%	52W Range	0.26 - 2.83	Perf YTD	-75.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.74%	ROI	-	52W High	-87.86%	Beta	0.82
Dividend TTM	-	Quick Ratio	1.83	Sales past 5Y	-0.78%	Gross Margin	95.53%	52W Low	32.75%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.83	EPS Y/Y TTM	47.20%	Oper. Margin	-225.98%	RSI (14)	46.85	Volatility	3.19% 8.57%
Employees	102	Debt/Eq	-	Sales Y/Y TTM	-11.21%	Profit Margin	-217.64%	Recom	1.25	Target Price	4.29
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-21.89%	Payout	-	Rel Volume	0.52	Prev Close	0.35
Sales Surprise	-54.47%	EPS Surprise	1.35%	Sales Q/Q	-70.21%	Earnings	May 15 BMO	Avg Volume	2.94M	Price	0.34
SMA20	-3.19%	SMA50	-3.99%	SMA200	-71.40%	Trades		Volume	1,562,680	Change	-1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-25	Initiated	William Blair	Outperform
Nov-15-24	Resumed	Citigroup	Buy	$5
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral	$5
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform	$2 → $7
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy	$7
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy	$6
Dec-04-23	Upgrade	Citigroup	Neutral → Buy	$1 → $5
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral	$7 → $1
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral	$11 → $5
Jun-15-23	Initiated	Guggenheim	Buy	$14
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight	$10
Jan-20-23	Initiated	Citigroup	Buy	$12
Nov-21-22	Initiated	Truist	Buy	$12
Oct-15-21	Resumed	BTIG Research	Buy	$32

Show Previous Ratings

May-20-25 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-16-25 03:06AM	Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +8.14%
12:19AM	Q1 2025 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 09:20AM	CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results (GlobeNewswire) -17.24%
08:15AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results (GlobeNewswire)
May-14-25 09:59AM	Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com) +6.09%
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-13-25 05:45PM	IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 07:00AM	Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer (GlobeNewswire) -13.21%
06:19AM	Bluebird pleads for deal support; Unity, Mersana lay off staff (BioPharma Dive)
Apr-23-25 10:12AM	Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting (GlobeNewswire)
Apr-04-25 04:05PM	Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 08:01AM	Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress (GlobeNewswire)
Mar-04-25 02:00AM	Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +5.90%
11:09PM	Loading…
Mar-03-25 11:09PM	Q4 2024 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -8.29%
08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:01AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-28-25 07:17AM	What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings (GuruFocus.com)
Feb-25-25 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.21%
Feb-24-25 04:01PM	Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 (GlobeNewswire)
Feb-07-25 04:05PM	Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.68% -6.67%
Jan-30-25 08:00AM	Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) +8.47%
Jan-10-25 12:49PM	Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? (Benzinga) -44.62%
06:02AM	Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) (GlobeNewswire)
06:00AM	Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer (GlobeNewswire)
Nov-14-24 02:06AM	Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
01:32AM	Q3 2024 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-24 08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +19.55%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results (GlobeNewswire)
08:00AM	Loading…
Nov-06-24 08:00AM	Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 (GlobeNewswire) +16.42%
Oct-15-24 11:01AM	SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc (GuruFocus.com)
Aug-13-24 08:20AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 08:00AM	Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024 (GlobeNewswire)
May-22-24 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-24 04:36PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.94%
03:15PM	Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
May-09-24 11:55AM	MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -27.50%
08:05AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:59AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-03-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 (GlobeNewswire)
Apr-04-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 08:41AM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.16%
Feb-28-24 09:49PM	Q4 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.58%
08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:35AM	Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 08:01AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.17%
Feb-21-24 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 (GlobeNewswire)
Feb-20-24 10:00AM	Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-01-24 08:00AM	Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +6.96%
Jan-05-24 08:01AM	Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-23 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15% +7.37%
Nov-08-23 02:42PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:13AM	Q3 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:10AM	Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 04:30PM	Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023 (GlobeNewswire) +7.21%
08:00AM	Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056 (GlobeNewswire)
Sep-07-23 06:30AM	The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure (American City Business Journals)
Sep-06-23 07:00AM	Mersana Therapeutics Announces Changes in Leadership (GlobeNewswire) +7.89%
Aug-18-23 09:35AM	After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN) (Zacks)
Aug-16-23 09:35AM	Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround (Zacks) -6.35%
Aug-08-23 09:40AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Mersana Therapeutics Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.24%
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +17.76%
03:14AM	4 big analyst cuts: Snap slashed to Hold, Southwest gets several downgrades (Investing.com)
Jul-27-23 09:34PM	EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc (GuruFocus.com) -72.63%
01:44PM	Mersana slashes half its staff, loses $400M in value after trial failure (American City Business Journals)
07:06AM	Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization (GlobeNewswire)
Jul-13-23 09:45AM	15 Best Penny Stocks To Buy Now (Insider Monkey)
Jul-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-16-23 10:43AM	Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold (Zacks) -10.80%
02:26AM	5 big analyst cuts: SoFi Technologies slashed with 3 downgrades, shares plunge (Investing.com)
Jun-15-23 09:32AM	Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser (Motley Fool) -59.27%
07:36AM	US FDA puts Mersana Therapeutics's ovarian cancer study on hold (Reuters)
07:30AM	Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials (GlobeNewswire)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +5.45%
Jun-02-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.82%
May-28-23 09:06AM	Those who invested in Mersana Therapeutics (NASDAQ:MRSN) a year ago are up 127% (Simply Wall St.)
May-24-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-23 08:35AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.82%
07:00AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.00%
May-03-23 08:00AM	Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire) +46.12%
May-02-23 08:00AM	Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023 (GlobeNewswire) -7.01%
Apr-26-23 04:05PM	Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 11:07AM	Getting In Cheap On Mersana Therapeutics, Inc. (NASDAQ:MRSN) Is Unlikely (Simply Wall St.) +5.54%
Apr-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-05-23 02:00PM	J.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside Potential (TipRanks)
Mar-16-23 11:20AM	Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More (Zacks) +6.37%
Mar-13-23 02:00PM	FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death (Benzinga)
07:54AM	UPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following death (Reuters)
07:30AM	Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial (GlobeNewswire)
Mar-10-23 07:10PM	Mersana Therapeutics Provides Statement About SVB (GlobeNewswire) -12.00%

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mandelia Ashish	VP, Chief Accounting Officer	Jan 15 '25	Option Exercise	0.00	8,685	0	61,073	Jan 17 07:27 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 16 '25	Sale	0.58	3,554	2,061	57,519	Jan 17 07:27 PM
Protopapas Anna	Director	Jan 15 '25	Option Exercise	0.00	21,250	0	176,678	Jan 17 07:26 PM
Protopapas Anna	Director	Jan 16 '25	Sale	0.58	8,637	5,009	168,041	Jan 17 07:26 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 15 '25	Option Exercise	0.00	19,791	0	265,721	Jan 17 07:25 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 16 '25	Sale	0.58	8,048	4,668	257,673	Jan 17 07:25 PM
Huber Martin H. Jr.	President, CEO	Jan 15 '25	Option Exercise	0.00	11,062	0	127,389	Jan 17 07:21 PM
Huber Martin H. Jr.	President, CEO	Jan 16 '25	Sale	0.58	4,514	2,618	122,875	Jan 17 07:21 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 15 '25	Option Exercise	0.00	20,833	0	129,863	Jan 17 07:20 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 16 '25	Sale	0.58	8,470	4,913	121,393	Jan 17 07:20 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 15 '25	Option Exercise	0.00	12,500	0	83,392	Jan 17 07:18 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 16 '25	Sale	0.58	5,096	2,956	78,296	Jan 17 07:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 15 '25	Option Exercise	0.00	14,583	0	74,811	Jan 17 07:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 16 '25	Sale	0.58	5,939	3,445	68,872	Jan 17 07:18 PM
Timothy B. Lowinger	Officer	Jan 16 '25	Proposed Sale	0.61	8,048	4,909		Jan 17 07:05 PM
Brian DeSchuytner	Officer	Jan 16 '25	Proposed Sale	0.61	8,470	5,167		Jan 17 07:05 PM
Alejandra Carvajal	Officer	Jan 16 '25	Proposed Sale	0.61	5,096	3,109		Jan 17 07:05 PM
Mohan Bala	Officer	Jan 16 '25	Proposed Sale	0.61	5,939	3,623		Jan 17 07:04 PM
Anna Protopapas	Director	Jan 16 '25	Proposed Sale	0.61	8,637	5,269		Jan 17 07:04 PM
Mohan Bala	Officer	Jan 14 '25	Proposed Sale	0.63	3,253	2,049		Jan 17 07:02 PM
Protopapas Anna	Director	Jan 14 '25	Option Exercise	0.00	16,750	0	161,619	Jan 16 05:25 PM
Protopapas Anna	Director	Jan 15 '25	Sale	0.63	6,191	3,900	155,428	Jan 16 05:25 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 14 '25	Option Exercise	0.00	4,783	0	54,179	Jan 16 05:25 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 15 '25	Sale	0.63	1,791	1,128	52,388	Jan 16 05:25 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 14 '25	Option Exercise	0.00	4,792	0	247,724	Jan 16 05:24 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 15 '25	Sale	0.63	1,794	1,130	245,930	Jan 16 05:24 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 14 '25	Option Exercise	0.00	6,250	0	111,361	Jan 16 05:23 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 15 '25	Sale	0.63	2,331	1,469	109,030	Jan 16 05:23 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 14 '25	Option Exercise	0.00	2,500	0	71,844	Jan 16 05:23 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 15 '25	Sale	0.63	952	600	70,892	Jan 16 05:23 PM
Protopapas Anna	Director	Jan 15 '25	Proposed Sale	0.64	6,191	3,962		Jan 16 05:21 PM
Lowinger Timothy B	Officer	Jan 15 '25	Proposed Sale	0.64	1,794	1,148		Jan 16 05:20 PM
DeSchuytner Brian	Officer	Jan 15 '25	Proposed Sale	0.64	2,331	1,492		Jan 16 05:19 PM
Protopapas Anna	Director	Jan 13 '25	Option Exercise	0.00	31,250	0	156,403	Jan 15 09:20 PM
Protopapas Anna	Director	Jan 14 '25	Sale	0.66	11,534	7,612	144,869	Jan 15 09:20 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 13 '25	Option Exercise	0.00	2,646	0	50,403	Jan 15 09:19 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 14 '25	Sale	0.66	1,007	665	49,396	Jan 15 09:19 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 13 '25	Option Exercise	0.00	9,375	0	246,415	Jan 15 09:18 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 14 '25	Sale	0.66	3,483	2,299	242,932	Jan 15 09:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 13 '25	Option Exercise	0.00	10,000	0	108,824	Jan 15 09:17 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 14 '25	Sale	0.66	3,713	2,451	105,111	Jan 15 09:17 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 13 '25	Option Exercise	0.00	8,958	0	72,674	Jan 15 09:17 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 14 '25	Sale	0.66	3,330	2,198	69,344	Jan 15 09:17 PM
Bala Mohan	SVP, Chief Development Officer	Jan 13 '25	Option Exercise	0.00	8,750	0	63,481	Jan 15 09:16 PM
Bala Mohan	SVP, Chief Development Officer	Jan 14 '25	Sale	0.66	3,253	2,147	60,228	Jan 15 09:16 PM
Protopapas Anna	Director	Jan 14 '25	Proposed Sale	0.63	11,534	7,266		Jan 15 09:15 PM
Bala Mohan	SVP, Chief Development Officer	Oct 25 '24	Option Exercise	0.00	6,250	0	56,615	Oct 29 04:43 PM
Bala Mohan	SVP, Chief Development Officer	Oct 28 '24	Sale	1.90	1,884	3,580	54,731	Oct 29 04:43 PM
Bala, Mohan	Officer	Oct 28 '24	Proposed Sale	2.04	1,884	3,843		Oct 29 04:26 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 01 '24	Option Exercise	0.00	50,000	0	108,511	Oct 07 05:48 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 02 '24	Sale	2.00	8,089	16,178	100,422	Oct 07 05:48 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 03 '24	Sale	1.96	5,598	10,972	94,824	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	77,403	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 02 '24	Sale	2.00	8,089	16,178	69,314	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 03 '24	Sale	1.96	5,598	10,972	63,716	Oct 07 05:48 PM
Bala Mohan	SVP, Chief Development Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	64,052	Oct 07 05:47 PM
Bala Mohan	SVP, Chief Development Officer	Oct 02 '24	Sale	2.00	8,089	16,178	55,963	Oct 07 05:47 PM
Bala Mohan	SVP, Chief Development Officer	Oct 03 '24	Sale	1.96	5,598	10,972	50,365	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 01 '24	Option Exercise	0.00	30,000	0	55,973	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 02 '24	Sale	2.00	4,855	9,710	51,118	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 03 '24	Sale	1.96	3,361	6,588	47,757	Oct 07 05:47 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	249,329	Oct 07 05:46 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 02 '24	Sale	2.00	8,089	16,178	241,240	Oct 07 05:46 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 03 '24	Sale	1.96	5,598	10,972	235,642	Oct 07 05:46 PM
Bala, Mohan	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:20 PM
Carvajal, Alejandra	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:19 PM
Brian DeSchuytner	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:18 PM
Timothy B. Lowinger	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:18 PM
Huber Martin H. Jr.	President, CEO	Sep 11 '24	Option Exercise	0.00	166,750	0	166,750	Sep 13 05:08 PM
Huber Martin H. Jr.	President, CEO	Sep 12 '24	Sale	1.76	50,423	88,744	116,327	Sep 13 05:08 PM
Huber, Martin H. Jr.	Officer, Director	Sep 12 '24	Proposed Sale	1.77	50,423	89,249		Sep 13 05:06 PM

SNDX

Syndax Pharmaceuticals Inc

MRSN

Mersana Therapeutics Inc

Upgrade your FINVIZ experience